EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Exploring Mechanisms of Lang Qing Ata in Non-Alcoholic Steatohepatitis Based on Metabolomics, Network Pharmacological Analysis, and Experimental Validation

Shupei Li, Hanlong Zhu, Qi Zhai, Yu Hou, Ya Yang, Haifeng Lan, Mingzuo Jiang, Ji Xuan

Drug Design, Development and Therapy · 2025-03 · Volume 19 · 1681-1701

DOI: 10.2147/dddt.s503757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-03. Verfasst von Shupei Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of Chin…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Network Pharmacology, Drugs, Chinese Herbal, Metabolomics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-alcoholic steatohepatitis (NASH), as a progressive form of Non-alcoholic fatty liver disease (NAFLD), poses a significant threat to human health as a prevalent and common condition, with a lack of safe and effective therapeutic options. However, the therapeutic effects and potential mechanisms of Lang Qing Ata (LQAtta) against NASH remain elusive. Materials and Methods: The components of LQAtta were identified using Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry (UHPLC-MS/MS). Subsequently, we employed network construction and analysis approaches within the field of network pharmacology. By integrating known databases and target prediction algorithms, which encompassed database-based target prediction, protein-protein interaction networks, as well as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, we unveiled the potential key targets and signaling pathways that these bioactive components might engage with. These discoveries were further validated in subsequent mouse models. An HFHC-induced NASH mouse model was used to validate the therapeutic effects and potential mechanisms of LQAtta on NASH.

Results

From the UHPLC-MS/MS analysis of LQAtta, a total of 1518 chemical components were identified, with 106 of them being absorbed into the bloodstream. Additionally, based on the acquisition of targets from both LQAtta and the NASH database, a total of 160 common targets were screened. KEGG enrichment analysis indicated that LQAtta may alleviate NASH by modulating pathways such as the Toll-like receptor signaling pathway, the NF-κB signaling pathway, and inflammation-related pathways. In vivo experimental results demonstrated that LQAtta could alleviate liver injury, steatosis, and inflammation induced by NASH, thereby slowing down the disease process. Additionally, LQAtta inhibited the expression and phosphorylation of NF-κB protein, playing a role in preventing NASH.

Conclusion

In this study, the combination of mass spectrometry analysis, network pharmacology, and animal experiments preliminarily elucidated the potential of LQAtta to treat NASH through NF-κB pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseNetwork PharmacologyDrugs, Chinese HerbalMetabolomicsAnimalsMiceDisease Models, AnimalMice, Inbred C57BLChromatography, High Pressure LiquidTandem Mass SpectrometryMaleHumans

Stichwörter der Autor:innen

Chinese herbal medicineNAFLDNASHmetabonomicsnetwork pharmacological analysis

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • Department of Gastroenterology, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
  • Department of Gastroenterology and Hepatology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, People's Republic of China.
  • Department of Gastroenterology, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.

Zitieren

APA

Li, S., Zhu, H., Zhai, Q., Hou, Y., Yang, Y., Lan, H., Jiang, M., & Xuan, J. (2025). Exploring Mechanisms of Lang Qing Ata in Non-Alcoholic Steatohepatitis Based on Metabolomics, Network Pharmacological Analysis, and Experimental Validation. Drug Design, Development and Therapy, Volume 19, 1681-1701. https://doi.org/10.2147/dddt.s503757

Vancouver

Li S, Zhu H, Zhai Q, Hou Y, Yang Y, Lan H, et al. Exploring Mechanisms of Lang Qing Ata in Non-Alcoholic Steatohepatitis Based on Metabolomics, Network Pharmacological Analysis, and Experimental Validation. Drug Design, Development and Therapy. 2025;Volume 19:1681-1701. doi:10.2147/dddt.s503757

BibTeX
@article{Li2025,
  author = {Li, Shupei and Zhu, Hanlong and Zhai, Qi and Hou, Yu and Yang, Ya and Lan, Haifeng and Jiang, Mingzuo and Xuan, Ji},
  title = {Exploring Mechanisms of Lang Qing Ata in Non-Alcoholic Steatohepatitis Based on Metabolomics, Network Pharmacological Analysis, and Experimental Validation},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {1681--1701},
  doi = {10.2147/dddt.s503757}
}
Kostenlos starten →